Suzanne R. Ellenberger is a notable inventor based in Reisterstown, MD (US). She has made significant contributions to the field of neuroprotective compounds, with a focus on antagonists of excitatory amino acid neurotransmitter receptors. Her work has implications for treating neurodegeneration and anxiety.

Latest Patents

Ellenberger holds 2 patents, including her latest inventions:

1. .omega.-[2-(phosphonoalkyl)phenyl]-2-aminoalkanoic acids as antagonists. This invention pertains to antagonists of excitatory amino acid neurotransmitter receptor antagonists, their method of preparation, and compositions containing them.

2. Antagonists of specific excitatory amino acid receptors. This invention involves methods and pharmaceutical compositions for treating, preventing, or reducing neurodegeneration associated with chronic central nervous system injuries and for the treatment of anxiety.

Career Highlights

Throughout her career, Ellenberger has worked with prominent companies such as Nova Pharmaceutical Corporation and Guilford Pharmaceuticals, Inc. Her expertise in neuropharmacology has led to advancements in therapeutic approaches for neurological conditions.

Collaborations

Ellenberger has collaborated with esteemed colleagues, including Waclaw J. Rzeszotarski and Maria E. Guzewska. Their joint efforts have contributed to the development of innovative solutions in the field of neuroprotective therapies.

Conclusion

Suzanne R. Ellenberger's work exemplifies the impact of innovation in the medical field, particularly in neuroprotection and anxiety treatment. Her patents and collaborations highlight her commitment to advancing therapeutic options for patients.